The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

Table 2

Clinical characteristics of the patients included for the validation of the CLL-IPI prognostic index.

	Patients (%)	Median (Q1, Q3)
Age (years)		65.7 (55.2–73.5)
<65	123 (47.9)
≥65	274 (52.1)
Sex
Male	162 (62.8)
Female	96 (37.2)
Lymphocyte count (×10^9/L)		13.2 (9.13–23.6)
≤20	184 (71.3)
>20	74 (28.7)
Hemoglobin (g/dL)		14.3 (13.2–15.3)
≤10	9 (3.5)
>10	249 (96.5)
Platelet count (×10^9/L)		181 (145–226)
≤100	12 (4.7)
>100	246 (95.3)
β2-microglobulin (mg/L)		2.10 (1.6–2.8)
≤3.5	223 (86.4)
>3.5	35 (13.6)
LDH (UI/L)		340 (298–398)
Enlarged node regions
≤2	205 (79.5)
>2	53 (20.5)
Splenomegaly
Yes	52 (20.2)
Not	206 (79.8)
Hepatomegaly
Yes	22 (8.5)
Not	236 (91.5)
Rai staging system
0	152 (58.9)
1–4	106 (41.1)
FISH
Del11q	20 (7.8)
Trisomy 12	33 (12.8)
Del13q	107 (41.5)
Del17p	10 (3.9)
Normal	88 (34.1)
IGHV mutation status
Positive	103 (39.9)
Negative	155 (60.1)
ZAP70
Positive	22 (20.0)
Negative	88 (80.0)
CD38
Positive	45 (23.4)
Negative	143 (76.1)

Q1: quartile 1; Q3: quartile 3; CLL-IPI: chronic lymphocytic leukemia international prognostic index.